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Abstract 
Purpose: Emerging data on breast cancer suggest that different breast cancer phenotypes may 
respond differently to available adjuvant therapies.  Optimal use of established and imaging methods, 
such as multiparametric magnetic resonance imaging (mpMRI) can simultaneously identify key 
functional parameters and provide unique imaging phenotypes of breast cancer.  Therefore, we have 
developed and implemented a new machine-learning informatic system that integrates clinical 
variables, derived from imaging and clinical health records, to compare with the 21-gene array assay, 
OncotypeDX.  
Materials and methods:  We tested our informatics modeling in a subset of patients (n=81) who had 
ER+ disease and underwent OncotypeDX gene expression and breast mpMRI testing.   The machine-
learning informatic method is termed Integrated Radiomic Informatic System (IRIS) was applied to the 
mpMRI, clinical and pathologic descriptors, as well as a gene array analysis. The IRIS method using 
an advanced graph theoretic model that transforms the patient space into a visualization heatmap and 
quantitative metrics. Summary statistics (mean and standard deviations) for the quantitative imaging 
parameters were obtained. Sensitivity and specificity and Area Under the Curve were calculated for the 
classification of the patients. Statistical significance was set at p ≤ 0.05. 
Results:  The OncotypeDX classification by IRIS model had sensitivity of 95% and specificity of 89% 
with AUC of 0.92 with 19(low), 50 (intermediate), 12(high) patients classified in each risk group. The 
breast lesion size was larger for the high-risk group (7.6±5.8cm2) and lower for both low risk 
(5.8±9.0cm2) and intermediate risk (4.6±5.4cm2) groups. There were significant differences in PK-DCE 
and ADC map values in each group. The lesion ADC map values for high- and intermediate-risk groups 
were significantly lower than the low-risk group (1.09 vs 1.38x10-3mm2/s).   
Conclusion:  These initial studies provide deeper understandings of imaging features and molecular 
gene array OncotypeDX score.  This insight provides the foundation to relate these imaging features 
to the assessment of treatment response for improved personalized medicine. 
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Introduction 
Integrating clinical health information with imaging as well as other biomarkers could be beneficial for 
defining variable cancer phenotypes. This accurate integration of what now is seemingly disparate data 
may improve our understanding of the complex nature of cancer. Ultimately, this integration may 
provide predictive markers with clinical benefits in certain cancer phenotypes. For example, in breast 
cancer, there is active research on how to predict the potential of local recurrence after conservative 
treatment. One such method to predict recurrence of the cancer is the Oncotype DX assay.  Oncotype 
DX is based on the mRNA expression by RT-PCR for estrogen receptor (ER) positive disease without 
the human growth factor receptor 2 (HER2-nu) overexpression and is tested on tissue obtained at 
biopsy or surgical samples 1,2.  Oncotype DX has been validated in prospective-retrospective studies 
as a prognostic tool in ER-positive patients treated with tamoxifen. It has been shown to be a predictive 
tool to identify patients most likely to benefit from the addition of adjuvant chemotherapy to endocrine 
therapy 1,3-5 
 
Figure 1. Illustration of the multi-subspace embedding and clustering method. The high dimensional 
patient space (left) consisting of different patients and their corresponding clinical and imaging 
parameter information is transformed into an integrated radiomics informatics system (IRIS) decision 
support system (right) using the multi-subspace embedding and clustering method. The IRIS results 
are represented using a heatmap where color scale (blue – red) indicates risk identified by each 
embedding while the hierarchical tree structure indicates the final patient classes (low, intermediate 
and high-risk) 
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Multiparametric (mp) radiological imaging can accurately detect and characterize breast lesions 
using advanced quantitative parameters 6,7. For example, using dynamic contrast-enhanced (DCE)-
MRI the vascularity and permeability of malignant lesions are characterized by rapid uptake of contrast 
agent followed by fast washout. Moreover, intra- and inter-cellular tumor environments of breast lesions 
are characterized by diffusion-weighted imaging (DWI), with the apparent diffusion coefficient (ADC) of 
water map. The ADC map provides a quantitative biophysical parameter that measures the cellularity 
of a lesion.  The challenge is to accurately combine mpMR images with clinical and pathologic features 
to stratify patients and identify the potential for cancer recurrence, similar to the costly Oncotype DX. 
To answer this challenge, we have developed a new machine-learning informatic method termed 
Integrated Radiomic Informatic System (IRIS), which can be applied to multiparametric MRI, clinical 
and pathologic descriptors, as well as a gene array analysis8,9. The purpose of this study is to test the 
IRIS algorithm by combining data from imaging and clinical health records to stratify patients into three 
risk groups: low, medium, and high risk and then compare with the OncotypeDX 21-gene array assay 
outcomes.   
 
Methods 
Clinical Subjects:  
All studies were performed in accordance with the institutional guidelines for clinical research under a 
protocol approved by our Institutional Review Board (IRB) and all HIPAA agreements were followed for 
this retrospective study. Patients were selected from the Johns Hopkins Integrated Breast Cancer 
Research Database developed by one on the authors and underwent MRI as part of the clinical health 
record review.  Of the patients with biopsy proven breast cancer who presented to our facility for 
bilateral breast MRI, 123 patients were identified to have both the OncotypeDX and an advanced MRI 
exam which included DCE and DWI.   Our inclusion criteria were: 1) breast imaging on 3T MRI scanner, 
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2) DCE and DWI MRI sequences, and 3) pathology proven diagnosis of ER+ breast cancer and 4) 
OncotypeDX having been performed on lesion tissue samples.  There were 81 patients with 84 lesions 
that satisfied the inclusion criteria.  
 
Figure 2. Demonstration of multiparametric breast MRI imaging of each risk group defined by the 
Oncotype DX.  Left Column) typical imaging of the low risk patient. Middle Column) typical imaging 
of the medium risk patient, and Right Column) typical imaging of a high-risk group patient.  Note, 
the PK-DCE all demonstrate malignant phenotype, however, by integrating all the data using IRIS, 
we were able to separate each Oncotype DX group.  
 
Histological Phenotyping: All breast cancers were categorized by histological phenotyping based 
upon immunohistochemistry(IHC). Estrogen and progesterone receptors (ER and PR), HER2-Nu by 
FISH, and Ki-67 proliferation index (%).  The Elston tumor grades for each lesion were distributed as    
Grade 1 (9%), Grade 2 (78%), and Grade 3 (13%), Histopathological data was obtained from the breast 
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pathology database. All patient demographics matched the current clinical criteria for the Oncotype DX 
test (ER positive).    
 
Theory: Multi-subspace embedding and clustering: 
We have developed a machine learning model that integrates different types of clinical and imaging 
parameters, which allows for the construction of a clinical support decision model. The inherent high 
dimensionality of the clinical and imaging parameters and any complex correlations within the data 
presents significant challenges for integration and visualization of the data. These challenges were 
solved using nonlinear dimensionality reduction (NLDR) method 10. Nonlinear dimensionality reduction 
algorithms transform and embeds a D dimensional space into a lower d dimensional manifold 
representation of D’s intrinsic dimensionality, where d<D.  The goal of the multi-subspace embedding 
and clustering method is to transform the patient space, represented as 𝑋 = {𝑥1, 𝑥2, … , 𝑥𝑛} ⊂ 𝑅
𝐷 where, 
xi represents the ith patient, n represents the number of patients and D represents the number of clinical 
and imaging parameters, into an integrated radiomics informatics decision support system (IRIS) 
visualized by a heatmap as shown in Figure 1. The steps of the IRIS system are outlined below8,9.  
In the first step, a D dimensional patient space is transformed into N d-dimensional subspaces 
where 𝑑 ∈ {2,3} . The second step involves transformation of each d-dimensional subspace, 𝑆𝑖 =
{𝑥1, 𝑥2, … , 𝑥𝑛} ∈ 𝑅
𝑑  ∀𝑖 ∈ {1,2, … , 𝑁}  into a one dimensional embedding, 𝑌𝑖 = {𝑥1, 𝑥2, … , 𝑥𝑛} ∈ 𝑅
1 ∀𝑖 ∈
{1,2, … ,𝑁}   using a nonlinear dimensionality reduction algorithm 11. In the third step, each one-
dimensional embedding, Yi is evaluated against the ground truth (OncotypeDX scale) based on the 
correlation coefficient, Ri between Yi and the ground truth. In this paper, we employed a simple 
evaluation metric of correlation coefficient. The aim of this step is to identify the optimal set of one 
dimensional embeddings, U, such that,  𝑅𝑖 ≥ 0.5, as shown in the following equation: 
𝑈 = {𝑌𝑖 ∈ 𝑌|𝑅𝑖 ≥ 0.5} ∀ 𝑖 ∈ {1,2,… , 𝑁} 
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In the fourth step, a hierarchical clustering algorithm is used to cluster the set, U as well as the patient 
space spanned by the one-dimensional embeddings in U to produce two clustering configurations. The 
first clustering configuration between different one-dimensional embeddings in U provides us 
information about the relationships between the clinical and imaging parameter embedding, which can 
be used to identify the each parameter’s importance, as well as remove redundant or similar 
embeddings. The second clustering configuration between each patient provides us input information 
about the relationship between different patients. This allows IRIS to identify patients clustered into 
different risk groups as well as classify any unknown patient into a relevant risk group.  
Clinical and imaging parameter importance:  
Using IRIS, the importance of each parameter, i is calculated by the percentage of embeddings in U 
that included the clinical and imaging parameter, i. The contribution of each parameter to the IRIS 
model allows for assessment of which parameters to keep and which to discard. 
Complex network analysis of informatics parameters 
a. Using IRIS, the high dimensional relationship between different clinical and imaging parameters 
was explored by modeling and analyzing a complex informatics network. Before modeling the 
complex network, the raw values corresponding to each clinical and imaging parameter were 
transformed into risk prediction score normalized in the range 0-1, such that zero corresponds 
to low risk and one corresponds to high risk. The risk prediction score for every parameter was 
calculated using the following steps: First, a correlation coefficient, ri between the values, yi 
spanned by the parameter, i across all the patients and corresponding Oncotype DX scores are 
calculated.  
b. Second, the range of clinical and imaging parameter values across all the patients are 
normalized from zero to one according to the following formula 
𝑧𝑖 = 
{
 
 
 
 𝑦𝑖 −min(𝑦𝑖)
max(𝑦𝑖) − min (𝑦𝑖)
, 𝑖𝑓 𝑟𝑖 ≥ 0   
1 − 
𝑦𝑖 −min(𝑦𝑖)
max(𝑦𝑖) − min (𝑦𝑖)
, 𝑖𝑓 𝑟𝑖 < 0
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Here zi represents the resultant risk prediction score for each parameter, i. 
 
 
Construction of network model of informatics parameters 
The complex informatics network, G was constructed from the multidimensional data, 𝑍 =
{𝑧1, 𝑧2, … , 𝑧𝐾} ∈ 𝑅
𝑛, where, zi represents the risk prediction score of the clinical and imaging parameter, 
i; K is the number of clinical and imaging parameters; and n is the number of patients. Furthermore, the 
complex network G is represented as G = (V,E) with 𝑉 = {𝑣1, 𝑣2, … , 𝑣𝐾}  being the set of K vertices 
representing the clinical and imaging parameters and E being the adjacency matrix indicating the 
interactions between the clinical and imaging parameters in the form of edge weights. The edge weight 
between any two vertices vi and vj was computed as follows 
𝐸𝑖𝑗 = 1 − 𝑐𝑜𝑟𝑟(𝑧𝑖 , 𝑧𝑗) 
We defined a neighborhood parameter, k to define the number of nearest neighbors each parameter 
can be connected to. The connectivity in the resulting complex network is dependent on the value of k 
chosen. If the value of k is chosen to be too large, the complex network may produce short circuit or 
spurious connections while a low value of k would produce a disconnected network 11. The value of k 
selected as 7, which approximates one-third of the total number of parameters.  
Statistical and topological characteristics of the complex network: 
The complex network was analyzed using graph summary metrics and centrality metrics 12,13 The 
average path length and diameter are the basic statistical metrics computed for any complex network. 
A path is defined as the set of edges connecting any two nodes and the sum of weights of these edges 
represent the path length. Average path length, as the name suggests, is the average of the path 
lengths across all pairs of nodes or clinical and imaging parameters. Diameter, on the other hand, is 
the maximum value among all the path lengths. Graph centrality metrics identify the most important 
clinical and imaging parameters in the complex network, also called the hub nodes 14,15. These hub 
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nodes influence the network properties. Furthermore, the probability of any incoming node connecting 
to these hub nodes is significantly higher than connecting to other nodes13. These hub nodes may 
correspond to the key clinical and imaging parameters that are predictors of breast cancer recurrence 
risk. In total, the following metrics were extracted from the complex network: Degree distribution, 
average path length, diameter, clustering coefficient and different centrality measures such as degree 
centrality, harmonics centrality, and betweenness centrality. (see appendix).  
Patient Classification 
We implemented patient classification using the hybrid IsoSVM feature transformation and classification 
algorithm 8 based on the Isomap 11 and the Support Vector Machine (SVM) algorithms 16 from the complex 
interaction network.  The imbalance in the number of patients in different risk groups was overcome by 
setting different misclassification penalties for different risk groups while training the SVM. The optimal 
values for the Isomap neighborhood parameter and the misclassification penalty were estimated using 
leave-one-out cross validation. 
 
Multiparametric Breast Imaging 
Patients were scanned on a 3T MRI system (3T Achieva, Philips Medical Systems, Best, The 
Netherlands) using a bilateral, dedicated four-channel, phased array breast coil (InVivo, Orlando, FL) 
with the patient in the prone position. Representative multiparametric breast imaging for the three risk 
groups as defined by OncotypeDX are illustrated in figure 2.  
Proton MRI Imaging: T2-weighted spin echo (TR/TE/IR=7142/70/220ms, Field of View 
(FOV)=350x350, matrix=220195, slice thickness(ST)=5mm, SENSE=2 and Averages(Ave)=2) and 
fast spoiled gradient echo (FSPGR) T1-weighted (TR/TE=5.4/2.3ms, FOV=350x350, matrix=548550, 
ST=3mm, SENSE=2 and Ave=1) sequences were acquired.    
Pharmacokinetic Dynamic Contrast-Enhanced MRI. The Pharmacokinetic (PK) DCE was obtained 
using non-fat-suppressed(FS), three-dimensional(3D), FSPGR T1-weighted (TR/TE=3.4/1.7ms, 
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FOV=350x350, matrix=256126, Flip angle=10, slice thickness=5mm, and Ave=1) sequences. Pre- 
and fourteen post- contrast images (temporal resolution=15s) after intravenous administration via a 
power injector of a GdDTPA contrast agent (0.2 mL/kg (0.1mmol/kg)).  
High Resolution Dynamic Contrast-Enhanced MRI. T1-weighted 3D GRE with 
FS(TR/TE=5.8/2.9ms, FOV=350x350, matrix=720720, Flip angle=13, ST=3mm, and Ave=1) were 
obtained pre and post the PK-DCE.   
Diffusion-Weighted Imaging. Diffusion-weighted imaging is acquired before contrast imaging using 
an FS fast spin echo EPI parallel imaging sequence (TR/TE/IR=9548/70ms, FOV=350x350, 
matrix=220195, SENSE=2, Ave=2, ST=3mm, b=0,200,600,800 s/mm2) on three planes and in less 
than three minutes. Trace apparent diffusion coefficient (ADC) maps were constructed using a 
monoexponential model from all three axes and interpolated to 2562. 
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MRI data analysis 
Clinical breast lesion classification methods: Breast lesions were identified on the breast MRI by a 
radiologist who was blinded to pathological results defined by the BIRADS lexicon17,18. Breast density 
was defined as extremely dense tissue, heterogeneously dense tissue, scattered fibroglandular tissue 
or primarily fatty tissue. Background parenchymal enhancement (BPE) was defined as minimal, mild, 
moderate or marked. Lesions were classified as a focus, a mass or non-mass enhancement (NME). 
Morphologic assessment was defined for masses, as shape (round, oval, irregular) margins 
(1=circumscribed, 2=not circumscribed 2a= irregular 2b = spiculated) and enhancement patterns 
(1=homogenous, 2=heterogeneous or 3=rim). For NME, distribution (1=focal, 2=regional, 3=linear 
 
Figure 3. Bar graphs of quantitative multiparametric MRI parameters from the NLDR model. 
There are significant differences between each group of patients.   
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4=diffuse, and 5=segmental) and enhancement pattern (homogenous, heterogeneous, clustered ring 
and clumped) were recorded.  We defined lesion morphology into seven classes (1=focal NME, 
2=regional NME, 3=linear or segmental NME, 4=circumscribed mass, 5=irregular mass, or 
6=spiculated mass).  
Pharmacokinetic Contrast Enhancement Metrics: Pharmacokinetic kinetic DCE MRI provides 
quantitative metrics of the volume transfer constant (Ktrans (min-1)) which characterize uptake of the 
contrast agent, the leakage within the extracellular extravascular space (ve (%)), and the transfer rate 
constant (kep (min-1)). Post-processing of the DCE exam was performed by a combined Brix and Tofts 
model 19-21 using DynaCad (InVivo, FL) software from the identified breast lesions.   
ADC Mapping: Regions of Interest(ROI) were drawn on normal appearing glandular tissue and breast 
lesions defined by DCE MRI.  Means and standard deviations were calculated for both tissue types.  
Ratios of lesion ADC to glandular tissue ADC (L/GT) were calculated from the equation on lesion and 
glandular tissue 22.   
Normalized ADC value =  
ADC value of Lesion
ADC value of glandular tissue
 
Statistical Analysis 
We computed summary statistics (mean and standard deviations) for the quantitative imaging 
parameters from the mpMRI.  An unpaired t-test was performed between each risk groups imaging 
parameters to determine statistical significance.  Sensitivity and specificity and Area Under the Curve 
were calculated to determine the classification of the patients. Statistical significance was set at p ≤ 
0.05. 
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Results 
Clinical Demographics:  
81 patients with 84 lesions of 123 patients identified who had both multiparametric MRI imaging and 
Oncotype assay were selected.  There were 19 (23%) patients with low risk (0-17), 50 (62%) patients 
with intermediate risk (18-31), and 12 (15%) patients with high risk (>31).  Seventy-four patients were 
ER+/PR+ and seven had only ER+ expression. There was no age difference (51-56y/o) between the 
patients. These data are summarized in Table 1.  The 42 patients not included in the study did not  
 
Figure 4. The   heat map demonstrates the stratification of the radiological parameters and risk groups 
correlated with the OncotypeDX score.  Note, there are high risk factors perceived in the low risk that 
may not been noted in clinical evaluations.  
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undergo a complete advanced mpMRI imaging session.  
 
Radiological Findings 
The high-risk group had the largest 
tumor size (7.6±5.8cm2).  Followed 
by the low risk group tumor size 
(5.8±9.0cm2)  and the intermediate 
risk group (4.6±5.4cm2).  For 
advanced MRI parameters, there 
were clear differences in each 
parameter and Oncotype risk 
groups. The PK-DCE 
parameters(Ktrans, EVF). The Ktrans 
values for the high- and 
intermediate-risk groups were higher 
(0.45 and 0.50 (1/min)) compared to the low-risk group (0.35(1/min)).  Similar results were noted for 
the other PK-DCE parameters.  the maximum contrast enhancement was largest for the high-risk 
group(523±145s), compared to the intermediate-risk(434±138s), and low-risk groups (489±139s).  
Similarly, the ADC map values from the high- and intermediate-risk patients in the lesion tissue were 
significantly lower (p<0.05) than those for the low-risk patients (1.09 vs 1.38x10-3mm2/s). However, the 
ADC map values in glandular tissue remained constant across all groups (2.14-2.17x10-3mm2/s).  The 
bar graphs are shown in Figure 3 
 
 
 
 
Figure 5. The Area under the Curve (AUC) graph of the top risk 
predictors in the NLDR model with the OncotypeDX score. The 
sensitivity was 95% and specificity was 82% with an AUC =0.92 (95% 
CI = 0.83-0.97). 
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IRIS Model 
The IRIS heatmap demonstrating the risk profile of each patient is shown in figure 4.  The IRIS 
system stratified the patients into three categories corresponding to low, intermediate and high-risk 
groups. The IRIS heatmap visualizes the individual contribution of each clinical and imaging 
parameter subspace using a color scale (low risk: blue to high risk: red). In addition, overall risk 
prediction of the patient is specified by the individual patient clusters. The top most important 
surrogate imaging and histological parameters determined from the clinical and imaging model are 
summarized in Table 2.  These were the ADC map values, the PK-DCE parameters, and Ki-67. The 
NLDR embedding that produced the best area under curve (AUC) consisted of Ki-67, ADC lesion 
value and ADC ratio resulting in the AUC of 0.92 with sensitivity of 95% and specificity of 89%. The 
ROC curve is shown in Figure 5.   
The topological graph theoretic metrics of integrated centrality and other different centrality measures 
for each informatics parameter are summarized in Table 3. The average path length between each 
parameter was 1.14, the correlation distance and diameter of the complex informatics network was 
2.18. The average clustering coefficient was 0.53, much higher than the clustering coefficient of Erdos-
Renyl random graph (CCER = 0.0228).   Figure 6 illustrates the complex interaction network and the 
integrated centrality of each parameter between all the variables, which provides insight into the diverse 
relationship between them.  The threshold on integrated centrality was chosen at 0.7 to determine the 
hub informatics parameters as there was a significant gap in the integrated centrality values between 
0.7 and 0.54. The resulting hub informatics parameters included Ki-67, ADC lesion and ADC ratio, DCE 
kinetic curve type, and DCE pharmacokinetic parameters (Permeability, Ktrans; extracellular 
extravascular fraction, EVF) 
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Figure 6. Visualization of integrated centrality on the complex   network. The nodes were color coded 
from blue to red with blue representing minimum and red representing maximum integrated centrality 
values. The top IRIS parameters demonstrate high integrated centrality metrics demonstrating their 
importance. 
 
 
Discussion  
We have introduced and demonstrated an advanced NLDR integrated clinical and imaging model (IRIS) 
to analyze the relationships and interactions between mpMRI parameters, clinical heath records, and 
histological variables compared with the OncotypeDX assay.  The IRIS model was able to consistently 
group patients into the three different categories based on data integration. Importantly, we defined 
imaging and clinical variables predictive of tumor recurrence compared to each category with the 
OncotypeDX. This separation of the data compared favorably to Oncotype DX and may lead to an 
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accurate assessment for recurrence that could complement or provide data similar to those obtained 
with proliferation assays like Oncotype DX.   For example, the most important parameters were ADC 
map values, PK-DCE metrics and Ki-67, all of which reflect the cellularity and vascularity of the tumor. 
This integrated model of imaging, clinical heath records, and IHC and histopathology data have the 
potential to describe features of cancer and may provide data for precision personalized care. This is 
the first study to employ an integrated graph theoretic model and machine learning using quantitative 
mpMRI and clinical variables in breast cancer compared with gene array data.  
 The categorization of the different risk groups from our model was strikingly consistent based 
on combined imaging and pathological IHC variables.  Indeed, the ADC map values were lower in the 
high and intermediate risk group consistent with the increased Ki-67 from histological analysis. The PK-
DCE parameters and lesion volume demonstrated similar characteristics.  Moreover, this report 
demonstrates by using advanced unsupervised machine learning methods in breast cancer, that 
integration of several variables can accurately separate those cancers into different risk stratifications 
consistent with the OncotypeDX results.   Finally, by using the complex interaction mapping, one can 
visualize the connections of each variable which may form the basis for even further predictive 
modeling.  
 The clinical and radiological parameters utilized in this study were derived from our clinical 
experience, since current treatment decision algorithms are based on standard clinicopathologic 
prognostic and predictive factors large datasets using clinical measures such as tumor size, node 
status, grade, ER, and HER2-nu 23-27.  Similarly, imaging features such as, breast density, lesion 
morphology, size, enhancement patterns as well as quantitative metrics (ADC map values and PK-
DCE) are routinely used in practice and therefore were familiar to the radiologist and are readily 
available. Finally, the OncotypeDX is used a predictive tool to identify patients most likely to benefit 
from the addition of adjuvant chemotherapy to endocrine therapy and has been validated in 
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prospective-retrospective studies 3-5.   Thus, the ability to combine these quantitative measures would 
be an important step in ensuring that “the right patient receives the right treatment”.   
 We developed an integrated informatics decision support system (IRIS) based on multi-
subspace embedding and clustering method for the purpose of diagnosis or prognosis. Furthermore, 
the complete multi-subspace embedding and clustering method is unsupervised and does not need 
any training data. The IRIS heatmap provides a visualization of relationship between different cancers 
along with a quantifiable embedding metrics. Using the IRIS heatmap, we would be able to identify a 
patient or a group of patients with the most similar informatics embedding metrics to a new patient with 
an unknown risk of recurrence.  Understanding these complex relationships between different 
embeddings can provide an insight on how these embeddings are related at biological level predicting 
recurrence of breast cancer.  Interestingly, the lesion size was not an accurate feature for categorizing 
cancers into the risk groups in this study.   The lesion size was largest for the highest risk group, but 
was smallest for the intermediate risk group, suggesting that lesion size alone is not an accurate 
predictor.  Differentiating and characterizing benign from invasive breast cancer is an important issue 
that was the focus of many different studies 7,28-32.  However, the prior studies typically only used a 
single or few MRI parameters for differentiating benign from invasive breast cancer.  We employed 
machine learning and graph theory methods to differentiate these entities. Our IRIS model incorporated 
pathophysiological and imaging characteristics of different breast tissue types, enabling a more 
predictive model in the tumor environment. However, there some limitations.  Our sample size was 
small, but based on known clinical and imaging variables and a proven gene array assay.  This report 
provides initial data for further testing on a larger cohort.  In addition, we plan on incorporating 
mammography and US into the model to provide additional data for improved classification and explore 
its use with Ductal Carcinoma in situ (DCIS).  
 In conclusion, these initial studies provide insight into the molecular underpinning of the 
surrogate imaging and clinical features and provide the foundation to relate these changes to histologic 
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and molecular pathology parameters.  The integration of these clinical and imaging parameters may 
help refine available prognostic and predictive markers, and improve clinical decision-making. 
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Appendix 
Clustering coefficient: 
The clustering coefficient defines the connectedness of the neighborhood of an informatics parameter. 
Clustering coefficient ranges from zero to one with zero representing completely disconnected 
neighborhood and one representing completely connected neighborhood. Mathematically, the 
clustering coefficient, i is defined as 
𝐶𝐶(𝑖) =  
2𝑒𝑖
𝑘𝑖(𝑘𝑖 − 1)
 
Here ei is the number of connected edges neighborhood of i, ki are the number of nodes in the 
neighborhood of i making 
𝑘𝑖(𝑘𝑖−1)
2
 the maximum possible number of edges in the neighborhood. 
Degree distribution: The degree distribution is the most fundamental metric calculated for any 
complex network. The degree distribution, P(k) is determined using the following equation 
𝑃(𝑘) =
1
𝑁
∑𝟏{deg(𝑖) = 𝑘}
𝑁
𝑖=1
 ∀𝑘 ∈ {7,8, … ,𝑁 − 1} 
Here, deg(i) represents the degree of the parameter, i which is defined as the total number of   
parameters that are directly connected to it; N is the number of parameters. 
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The degree distribution enables us to identify whether the network is a scale-free network or not. For 
scale free networks, the degree distribution follows the power law 𝑃(𝑘) ∝ 𝑘−𝛾 , with the value of  𝛾 
ranging between 2 and 3. Scale free networks are characterized by the presence of few highly 
connected hub nodes that influence the network properties and may correspond to the key parameters 
that are predictors of breast cancer recurrence risk 13. 
Centrality measures: The Centrality measures determine the importance of each informatic parameter 
in the complex network. The most widely used measures of centrality are betweenness, Harmonic and 
Degree centrality 14,15,33. We use three centrality measures, each centrality measure highlighting a 
different importance property of the network. 
a) Betweenness centrality: Betweenness centrality quantifies the amount of information that flows 
through each parameter 14. It is defined as the number of shortest paths that pass through a 
parameter, given by the following equation: 
𝐶𝐵(𝑖) =  ∑
𝑁𝑠𝑡(𝑖)
𝑁𝑠𝑡
𝑠≠𝑖≠𝑡
 
Here, Nst is the total number of shortest paths between the   parameters, s and t and Nst(i) is the 
total number of shortest paths between s and t that pass through i. 
b) Harmonic centrality: Harmonic centrality of a parameter is defined as the sum of inverse of all 
geodesic distances (path lengths) from that parameter to all the other   parameters15. 
Mathematically, harmonic centrality of an   parameter, i is given by the following equation: 
𝐶𝐻(𝑖) =
1
𝑁 − 1
∑
1
𝐺(𝑠, 𝑖)
𝑁
𝑠=1
𝑠≠𝑖
 
Here G(s,i) is the geodesic distance or path length between the     parameters s and i.  
c) Degree centrality: Degree centrality or degree is defined as the total number of parameters, where  
each parameter is connected to in the complex network.  
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d) Integrated centrality: Each centrality measure signifies the importance of each parameter based 
on a pre-define characteristic. Where, the significance of each parameter across all centrality 
indices can be defined using integrated centrality 34 as shown in the following equation: 
𝐶𝑖𝑛𝑡(𝑖) =
1
3
(
𝐶𝐵(𝑖)
max(𝐶𝐵)
+ 
𝐶𝐻(𝑖)
max(𝐶𝐻)
+ 
𝐶𝐷(𝑖)
max(𝐶𝐷)
) 
Here, Cint corresponds to the integrated centrality of the parameter, i; CB, CH and CD represent the 
betweenness, harmonic and degree centralities of the parameter, i respectively and max () extracts the 
maximum values of each centrality measure across all the   parameters.  
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Table 1 –Patient clinical and demographics 
   
Clinical  Mean Standard Deviation  
Age 53 10 
Tumor Grade 
(Elson) 
    
T1 8   
T2 61   
T3 12   
Phenotype     
ER+ 81   
PR+ 74   
Her2-Nu+ 1   
Triple Negative 0   
Ki67 (%) 29 16 
ODX     
Low 19   
intermediate 50   
high 12   
   
ER=Estrogen Receptor, PR-Progesterone Receptor, ODX=OncotypeDX,  
 
Table 2. Summary of the IRIS importance values of different informatic parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Informatics parameter 
IRIS heatmap 
ranking 
Ki-67 1 
ADC Ratio 2 
Ktrans 3 
ADC Lesion 4 
Percent initial uptake 5 
Extra Vascular Fraction 6 
Volume 7 
Type of mass 8 
ADC Glandular 9 
Breast Density 10 
Lesion Size 10 
Margin 10 
Lesion Type+Margin 10 
Internal enhancement 10 
Max Signal Intensity  10 
Curve type 10 
Time to Peak enhancement 10 
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Table 3 Summary of the centrality values of different informatics parameters. 
 
Informatics parameter Betweenness 
centrality 
Harmonic 
centrality 
Degree 
centrality 
Integrated 
centrality 
ADC Ratio 46.00 1.49 5.00 12.82 
Curve type 33.00 1.06 7.00 9.20 
Internal Enhancement 29.00 0.75 3.00 8.08 
ADC Lesion 17.00 1.47 5.00 4.74 
Ktrans 16.00 0.95 6.00 4.46 
ADC Glandular 15.00 0.73 3.00 4.18 
Ki-67 10.00 0.80 3.00 2.79 
Type of mass 9.00 0.78 3.00 2.51 
Lesion Size 7.00 0.65 3.00 1.95 
Breast Density 5.00 0.66 3.00 1.39 
Lesion Type+Margin 3.00 0.76 4.00 0.84 
Time to peak 
enhancement 
1.00 0.77 4.00 0.28 
Margin  0.00 0.77 3.00 0.00 
Percent initial uptake 0.00 0.85 3.00 0.00 
Max Signal Intensity  0.00 0.63 3.00 0.00 
Volume 0.00 0.59 3.00 0.00 
Extra Vascular Fraction 0.00 0.82 3.00 0.00 
 
ADC=Apparent Diffusion Coefficient    
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Figures 
 
Figure 1. Illustration of the multi-subspace embedding and clustering method. The high dimensional 
patient space (left) consisting of different patients and their corresponding clinical and imaging 
parameter information is transformed into an integrated radiomics informatics system (IRIS) decision 
support system (right) using the multi-subspace embedding and clustering method. The IRIS results 
are represented using a heatmap where color scale (blue – red) indicates risk identified by each 
embedding while the hierarchical tree structure indicates the final patient classes (low, intermediate 
and high-risk) 
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Figure 2. Demonstration of multiparametric breast MRI imaging of each risk group defined by the 
Oncotype DX.  Left Column) typical imaging of the low risk patient. Middle Column) typical 
imaging of the medium risk patient, and Right Column) typical imaging of a high-risk group patient.  
Note, the PK-DCE all demonstrate malignant phenotype, however, by integrating all the data using 
IRIS, we were able to separate each Oncotype DX group.  
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Figure 3. Bar graphs of quantitative multiparametric MRI parameters from the NLDR model. 
There are significant differences between each group of patients.   
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Figure 4. The   heat map demonstrates the stratification of the radiological parameters and 
risk groups correlated with the OncotypeDX score.  Note, there are high risk factors perceived 
in the low risk that may not been noted in clinical evaluations.  
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Figure 5. The Area under the Curve (AUC) graph of the top risk predictors in the NLDR model 
with the OncotypeDX score. The sensitivity was 95% and specificity was 82% with an AUC =0.90 
(95% CI = 0.83-0.97). 
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Figure 6. Visualization of integrated centrality on the complex   network. The nodes were color coded 
from blue to red with blue representing minimum and red representing maximum integrated centrality 
values. The top IRIS parameters demonstrate high integrated centrality metrics demonstrating their 
importance. 
 
 
 
 
 
